AIMS: Pleomorphic lobular carcinoma in situ (PLCIS) of the breast is a distinctive entity, but its behaviour and management are unclear. The purpose of this study was to review a relatively large number of cases and to evaluate the risk of recurrence. METHODS AND RESULTS: Cases of PLCIS (n = 47) from a 12-year period were reviewed. The clinical, radiological and pathological findings were recorded. Immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR) and HER2 was performed. Thirty-one patients had no concurrent breast cancer or past history of breast cancer, and six (19.4%) of these had local recurrence; all tumours (four invasive carcinoma and two PLCIS) were ipsilateral. Younger age at presentation was a risk factor for local recurrence: patients with recurrence had a mean age (range) of 52.5 years (44-59 years), versus 60.6 years (40-81 years) for those without (P = 0.03). Three of 31 patients were treated with radiation therapy (RT), and none of these developed local recurrence. PLCIS had an adverse ER/PR/HER2 molecular profile, with at least 41.2% of the cases overexpressing HER2. Moreover, at least 11.7% of the cases were triple-negative. CONCLUSIONS: This study included the largest number of patients who had no concurrent breast cancer or past history of breast cancer with the longest clinical follow-up, providing insights into management practices for PLCIS and the risk of recurrence.
AIMS: Pleomorphic lobular carcinoma in situ (PLCIS) of the breast is a distinctive entity, but its behaviour and management are unclear. The purpose of this study was to review a relatively large number of cases and to evaluate the risk of recurrence. METHODS AND RESULTS: Cases of PLCIS (n = 47) from a 12-year period were reviewed. The clinical, radiological and pathological findings were recorded. Immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR) and HER2 was performed. Thirty-one patients had no concurrent breast cancer or past history of breast cancer, and six (19.4%) of these had local recurrence; all tumours (four invasive carcinoma and two PLCIS) were ipsilateral. Younger age at presentation was a risk factor for local recurrence: patients with recurrence had a mean age (range) of 52.5 years (44-59 years), versus 60.6 years (40-81 years) for those without (P = 0.03). Three of 31 patients were treated with radiation therapy (RT), and none of these developed local recurrence. PLCIS had an adverse ER/PR/HER2 molecular profile, with at least 41.2% of the cases overexpressing HER2. Moreover, at least 11.7% of the cases were triple-negative. CONCLUSIONS: This study included the largest number of patients who had no concurrent breast cancer or past history of breast cancer with the longest clinical follow-up, providing insights into management practices for PLCIS and the risk of recurrence.
Authors: Sarah L Blair; Derek K Emerson; Swati Kulkarni; E Shelley Hwang; Vanessa Malcarne; David W Ollila Journal: Breast J Date: 2012-12-10 Impact factor: 2.431
Authors: Megan E Sullivan; Seema A Khan; Yurdanur Sullu; Carol Schiller; Barbara Susnik Journal: Arch Pathol Lab Med Date: 2010-07 Impact factor: 5.534
Authors: Yunn-Yi Chen; Eun-Sil Shelley Hwang; Ritu Roy; Sandy DeVries; Joseph Anderson; Chrystal Wa; Patrick L Fitzgibbons; Timothy W Jacobs; Gaetan MacGrogan; Hans Peterse; Anne Vincent-Salomon; Taku Tokuyasu; Stuart J Schnitt; Frederic M Waldman Journal: Am J Surg Pathol Date: 2009-11 Impact factor: 6.394
Authors: David J Dabbs; Stuart J Schnitt; Felipe C Geyer; Britta Weigelt; Frederick L Baehner; Thomas Decker; Vincenzo Eusebi; Stephen B Fox; Shu Ichihara; Sunil R Lakhani; Jose Palacios; Emad Rakha; Andrea L Richardson; Fernando C Schmitt; Puay-Hoon Tan; Gary M Tse; Anne Vincent-Salomon; Ian O Ellis; Sunil Badve; Jorge S Reis-Filho Journal: Am J Surg Pathol Date: 2013-07 Impact factor: 6.394
Authors: Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Marina De Brot; Starr Koslow Mautner; Shirin Muhsen; Victor P Andrade; Anita Mamtani; Melissa Murray; Dilip Giri; Rita A Sakr; Edi Brogi; Tari A King Journal: Breast Cancer Res Treat Date: 2017-06-13 Impact factor: 4.872
Authors: Meghan R Flanagan; Mara H Rendi; Kristine E Calhoun; Benjamin O Anderson; Sara H Javid Journal: Ann Surg Oncol Date: 2015-04-17 Impact factor: 5.344
Authors: Beth T Harrison; Faina Nakhlis; Deborah A Dillon; T Rinda Soong; Elizabeth P Garcia; Stuart J Schnitt; Tari A King Journal: Mod Pathol Date: 2020-01-13 Impact factor: 7.842
Authors: Isabelle L Crary; Elizabeth U Parker; Kathryn P Lowry; Pranav P Patwardhan; Thing Rinda Soong; Sara H Javid; Kristine E Calhoun; Meghan R Flanagan Journal: Ann Surg Oncol Date: 2022-07-08 Impact factor: 4.339
Authors: M Gabriela Kuba; Melissa P Murray; Kristen Coffey; Catarina Calle; Monica Morrow; Edi Brogi Journal: Mod Pathol Date: 2021-04-06 Impact factor: 7.842